{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:55Z","timestamp":1793118835292,"version":"4.5.0"},"reference-count":73,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The objective of this study was to perform a systematic review of the literature on vaccine responsiveness in patients who have received anti-CD20 therapy. PubMed and EMBASE were searched up to 4 January 2021 to identify studies of vaccine immunogenicity in patients treated with anti-CD20 therapy, including patients with hematologic malignancy or autoimmune disease. The primary outcomes were seroprotection (SP), seroconversion (SC), and\/or seroresponse rates for each type of vaccine reported. As the pandemic influenza vaccine (2009 H1N1) has standardized definitions for SP and SC, and represented a novel primary antigen similar to the COVID-19 vaccine, meta-analysis was conducted for SC of studies of this vaccine. Pooled estimates, relative benefit ratios (RBs), and 95% confidence intervals (CIs) were calculated using a random-effects model. Thirty-eight studies (905 patients treated with anti-CD20 therapy) were included (19 studies of patients with hematologic malignancies). Patients on active (&amp;lt;3 months since last dose) anti-CD20 therapy had poor responses to all types of vaccines. The pooled estimate for SC after 1 pandemic influenza vaccine dose in these patients was 3% (95% CI, 0% to 9%), with an RB of 0.05 (95% CI, 0-0.73) compared with healthy controls and 0.22 (95% CI, 0.09-0.56) compared with disease controls. SC compared with controls seems abrogated for at least 6 months following treatment (3-6 months post anti-CD20 therapy with an RB of 0.50 [95% CI, 0.24-1.06] compared with healthy and of 0.44 [95% CI, 0.23-0.84] compared with disease controls). For all vaccine types, response to vaccination improves incrementally over time, but may not reach the level of healthy controls even 12 months after therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004629","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:47:06Z","timestamp":1624290426000},"page":"2624-2643","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":113,"title":["Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-1501","authenticated-orcid":false,"given":"Abi","family":"Vijenthira","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"},{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9306-2945","authenticated-orcid":false,"given":"Inna","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"},{"name":"Division of Allergy and Immunology, St. Michael\u2019s Hospital, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"},{"name":"Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada;"},{"name":"Division of Hematology\/Oncology, St. Michael\u2019s Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"3","key":"2021062115421018600_B1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.21203","article-title":"Epidemiology and outcomes of serious influenza-related infections in the cancer population","volume":"104","author":"Cooksley","year":"2005","journal-title":"Cancer."},{"issue":"12","key":"2021062115421018600_B2","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol Infect."},{"issue":"1","key":"2021062115421018600_B3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40011-011-0008-7","article-title":"Viral infections in immunocompromised hosts","volume":"82","author":"Ramamurthy","year":"2012","journal-title":"Proc Natl Acad Sci India Sect B Biol Sci."},{"issue":"25","key":"2021062115421018600_B4","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood."},{"issue":"7821","key":"2021062115421018600_B5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature."},{"issue":"5","key":"2021062115421018600_B6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"27","key":"2021062115421018600_B7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"10269","key":"2021062115421018600_B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet."},{"key":"2021062115421018600_B9","article-title":"Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine","author":"Sadoff","journal-title":"N Engl J Med."},{"issue":"1","key":"2021062115421018600_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.25039","article-title":"Good and bad memories following rituximab therapy","volume":"62","author":"St Clair","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"16","key":"2021062115421018600_B11","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1182\/blood-2011-03-344051","article-title":"Immunologic effects of rituximab on the human spleen in immune thrombocytopenia","volume":"118","author":"Audia","year":"2011","journal-title":"Blood."},{"issue":"7","key":"2021062115421018600_B12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2021062115421018600_B13","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","article-title":"Pharmacodynamics of rituximab in kidney allotransplantation","volume":"6","author":"Genberg","year":"2006","journal-title":"Am J Transplant."},{"issue":"4","key":"2021062115421018600_B14","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther."},{"issue":"11","key":"2021062115421018600_B15","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/TP.0b013e3181735723","article-title":"B cell survival in intragraft tertiary lymphoid organs after rituximab therapy","volume":"85","author":"Thaunat","year":"2008","journal-title":"Transplantation."},{"issue":"6","key":"2021062115421018600_B16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant."},{"issue":"9","key":"2021062115421018600_B17","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2007-11-123844","article-title":"The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells","volume":"111","author":"Mamani-Matsuda","year":"2008","journal-title":"Blood."},{"issue":"12","key":"2021062115421018600_B18","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0800555105","article-title":"Maintenance of the plasma cell pool is independent of memory B cells","volume":"105","author":"Ahuja","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2021062115421018600_B19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14760584.2016.1193438","article-title":"Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients","volume":"15","author":"Cheng","year":"2016","journal-title":"Expert Rev Vaccines."},{"issue":"1","key":"2021062115421018600_B20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol."},{"issue":"7","key":"2021062115421018600_B21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2021062115421018600_B22","author":"World Health Organization"},{"key":"2021062115421018600_B23","author":"US Food and Drug Administration"},{"key":"2021062115421018600_B24","author":"Wells","year":"2011"},{"issue":"1","key":"2021062115421018600_B25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med."},{"issue":"3","key":"2021062115421018600_B26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid-Based Healthc."},{"key":"2021062115421018600_B27","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"2021062115421018600_B28","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2019","edition":"2nd ed"},{"issue":"11","key":"2021062115421018600_B29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health."},{"issue":"9","key":"2021062115421018600_B30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3109\/0284186X.2014.914243","article-title":"The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab","volume":"53","author":"Berglund","year":"2014","journal-title":"Acta Oncol."},{"issue":"3","key":"2021062115421018600_B31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1634\/theoncologist.2011-0342","article-title":"A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A\/H1N1 vaccine in cancer outpatients","volume":"17","author":"Hottinger","year":"2012","journal-title":"Oncologist."},{"issue":"1","key":"2021062115421018600_B32","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"2021062115421018600_B33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcv.2010.11.013","article-title":"Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment","volume":"50","author":"Mackay","year":"2011","journal-title":"J Clin Virol."},{"issue":"9","key":"2021062115421018600_B34","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3109\/10428194.2011.584003","article-title":"The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies","volume":"52","author":"Monkman","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2021062115421018600_B35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"6","key":"2021062115421018600_B36","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood."},{"issue":"7","key":"2021062115421018600_B37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3109\/10428194.2012.742524","article-title":"Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant","volume":"54","author":"Villa","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"11","key":"2021062115421018600_B38","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood."},{"issue":"8","key":"2021062115421018600_B39","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","article-title":"The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab","volume":"29","author":"Arad","year":"2011","journal-title":"Vaccine."},{"issue":"2","key":"2021062115421018600_B40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"de Lavallade","year":"2011","journal-title":"Haematologica."},{"issue":"14","key":"2021062115421018600_B41","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine."},{"issue":"2","key":"2021062115421018600_B42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","article-title":"Rituximab-treated patients have a poor response to influenza vaccination","volume":"33","author":"Eisenberg","year":"2013","journal-title":"J Clin Immunol."},{"issue":"5","key":"2021062115421018600_B43","first-page":"723","article-title":"Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination","volume":"31","author":"Muller","year":"2013","journal-title":"Clin Exp Rheumatol."},{"issue":"9","key":"2021062115421018600_B44","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2012-06-438689","article-title":"Seasonal and pandemic (A\/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens","volume":"120","author":"Bedognetti","year":"2012","journal-title":"Blood."},{"issue":"8","key":"2021062115421018600_B45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4161\/hv.29094","article-title":"Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies","volume":"10","author":"Ide","year":"2014","journal-title":"Hum Vaccin Immunother."},{"issue":"12","key":"2021062115421018600_B46","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.bbmt.2015.08.010","article-title":"Robust vaccine responses in adult and pediatric cord blood transplantation recipients treated for hematologic malignancies","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021062115421018600_B47","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bbmt.2009.07.018","article-title":"Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation","volume":"15","author":"Small","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"2021062115421018600_B48","author":"Surveillance, Epidemiology, and End Results Program","year":"2017"},{"key":"2021062115421018600_B49","author":"Plotkin","year":"2013","edition":"6th ed"},{"issue":"1","key":"2021062115421018600_B50","first-page":"19","article-title":"Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients","volume":"8","author":"Puissant-Lubrano","year":"2010","journal-title":"Exp Clin Transplant."},{"issue":"7","key":"2021062115421018600_B51","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2021062115421018600_B52","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","article-title":"Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens","volume":"186","author":"Bedognetti","year":"2011","journal-title":"J Immunol."},{"key":"2021062115421018600_B53","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","article-title":"Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome","volume":"10","author":"Colucci","year":"2019","journal-title":"Front Immunol."},{"issue":"7","key":"2021062115421018600_B54","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2006-04-006981","article-title":"Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants","volume":"108","author":"Jaffe","year":"2006","journal-title":"Blood."},{"key":"2021062115421018600_B55","first-page":"63","article-title":"Haemagglutination-inhibiting antibody to influenza virus","volume":"115","author":"de Jong","year":"2003","journal-title":"Dev Biol (Basel)."},{"issue":"suppl 3","key":"2021062115421018600_B56","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol."},{"issue":"10","key":"2021062115421018600_B57","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol."},{"issue":"10242","key":"2021062115421018600_B58","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0140-6736(20)31142-9","article-title":"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis","volume":"395","author":"Chu","year":"2020","journal-title":"Lancet."},{"issue":"3","key":"2021062115421018600_B59","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbmt.2010.10.002","article-title":"Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients","volume":"17","author":"Issa","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021062115421018600_B60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ene.12132","article-title":"Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"20","author":"Kim","year":"2013","journal-title":"Eur J Neurol."},{"issue":"26","key":"2021062115421018600_B61","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood."},{"issue":"14","key":"2021062115421018600_B62","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology."},{"issue":"12","key":"2021062115421018600_B63","doi-asserted-by":"crossref","first-page":"e93222","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight."},{"issue":"10","key":"2021062115421018600_B64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.medcli.2019.02.003","article-title":"Antibody responses to influenza vaccine in patients on biological therapy: results of RIER cohort study","volume":"153","author":"Richi","year":"2019","journal-title":"Med Clin (Barc)."},{"issue":"12","key":"2021062115421018600_B65","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2021062115421018600_B66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"9","key":"2021062115421018600_B67","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/kez045","article-title":"Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study","volume":"58","author":"B\u00fchler","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"2021062115421018600_B68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood."},{"issue":"9","key":"2021062115421018600_B69","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/j.clml.2020.04.006","article-title":"The use of 20% subcutaneous immunoglobulin replacement therapy in patients with B cell non-Hodgkin lymphoma with humoral immune dysfunction after treatment with rituximab","volume":"20","author":"Mustafa","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"2021062115421018600_B70","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"Effect of rituximab on human in vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"2021062115421018600_B71","doi-asserted-by":"crossref","first-page":"e12959","DOI":"10.1111\/acel.12959","article-title":"Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging","volume":"18","author":"Avivi","year":"2019","journal-title":"Aging Cell."},{"issue":"9","key":"2021062115421018600_B72","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10067-020-05042-2","article-title":"Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study","volume":"39","author":"Richi","year":"2020","journal-title":"Clin Rheumatol."},{"issue":"5","key":"2021062115421018600_B73","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/12\/2624\/1810358\/advancesadv2021004629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/12\/2624\/1810358\/advancesadv2021004629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:48:08Z","timestamp":1624290488000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/12\/2624\/476201\/Vaccine-response-following-anti-CD20-therapy-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,6,21]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004629","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}